Abstract:Despite the treatment advancements in pancreatic ductal adenocarcinoma, 5‐year survival rates are still below 10%. Analyzing the phosphoproteome of 42 tumors, three subtypes with intrinsic and stromal features were revealed, each displaying kinase activity patterns with potential treatment options. Kinase activities associated with specific mutations, and correlated with clinical prognosis. This study provides insights for tailored and combination strategies. Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a limited number of known driver mutations but considerable cancer cell heterogeneity. Phosphoproteomics provides a direct read‐out of aberrant signaling and the resultant clinically relevant phenotype. Mass spectrometry (MS)‐based proteomics and phosphoproteomics were applied to 42 PDAC tumors. Data encompassed over 19 936 phosphoserine or phosphothreonine (pS/T; in 5412 phosphoproteins) and 1208 phosphotyrosine (pY; in 501 phosphoproteins) sites and a total of 3756 proteins. Proteome data identified three distinct subtypes with tumor intrinsic and stromal features. Subsequently, three phospho‐subtypes were apparent: two tumor intrinsic (Phos1/2) and one stromal (Phos3), resembling known PDAC molecular subtypes. Kinase activity was analyzed by the Integrative iNferred Kinase Activity (INKA) scoring. Phospho‐subtypes displayed differential phosphorylation signals and kinase activity, such as FGR and GSK3 activation in Phos1, SRC kinase family and EPHA2 in Phos2, and EGFR, INSR, MET, ABL1, HIPK1, JAK, and PRKCD in Phos3. Kinase activity analysis of an external PDAC cohort supported our findings and underscored the importance of PI3K/AKT and ERK pathways, among others. Interestingly, unfavorable patient prognosis correlated with higher RTK, PAK2, STK10, and CDK7 activity and high proliferation, whereas long survival was associated with MYLK and PTK6 activity, which was previously unknown. Subtype‐associated activity profiles can guide therapeutic combination approaches in tumor and stroma‐enriched tissues, and emphasize the critical role of parallel signaling pathways. In addition, kinase activity profiling identifies potential disease markers with prognostic significance.

Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer

Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma

Glycogen Synthase Kinase 3β in Pancreatic Cancer and Its Implications in Chemotherapy and Radiation Therapy.

GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties

GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals

Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response

Targeting KRAS in PDAC: A New Way to Cure It?

Glycogen synthase kinase-3β inhibitors as a novel promising target in the treatment of cancer: Medicinal Chemistry Perspective

Shrna Silencing Glycogen Synthase Kinase-3 Beta Inhibits Tumor Growth and Angiogenesis in Pancreatic Cancer

p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)

A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies

Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer

Multifaceted Effects of Kinase Inhibitors on Pancreatic Cancer Cells Reveals Pivotal Entities with Therapeutic Implications

G3BP2 promotes tumor progression and gemcitabine resistance in PDAC via regulating PDIA3-DKC1-hENT in a stress granules-dependent manner

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies

Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies

Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?

Pan-KRAS inhibitors suppress proliferation through feedback regulation in pancreatic ductal adenocarcinoma

Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues

Glycogen Synthase Kinase 3 Beta In Tumorigenesis And Oncotherapy